Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Enso Ventures United States

Enso Ventures is a Venture Capital firm that was founded in 2010 and based in London with an additional office in New York. The firm is looking to provide equity capital to high growth companies in the life science space. The firm is currently interested in companies located in Europe, Russia and the US and is looking to make approximately 2-3 investments over the next 6-9 months.

Website:
http://www.ensoventures.com/
Year Founded
2010
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Sergei Petukhov
Partner 

Excel Venture Management United States

Excel Venture Management is a venture capital firm that was founded in 2008 and is based in Boston, Massachusetts. The firm has managed one fund with committed capital of $125 million, and the firm is currently raising the second fund. Excel Venture Management seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $3 million to $ 5million. The firm plans to invest in 4-5 companies over the next 6-9 months and prefers to invest in companies based in US.

Website:
http://www.excelvm.com
Year Founded
2008
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Eric Zimmerman
Kevin Liang

Flagship Ventures

Flagship Ventures is an early-stage venture capital firm founded in 2 and located in Cambridge MA. The firm has $9 million AUM. Flagship Ventures invests in therapeutics and in medical technology and makes initial allocation of typically $5-$5 million with the possibility of follow-on investments for a total commitment of up to $7 million-$15 million.
Website:
www.flagshipventures.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
David Berry
Partner 

Foundation Fighting Blindness

The Foundation Fighting Blindness is a foundation founded in 1971 and headquartered in Colombia Maryland. The foundation typically makes allocations to companies in the range of $1-$8 million and is capable of providing $1-$15 over the investments lifetime. The firm does not look to take an equity position in companies but they do look for an ROI to return capital to the fund upon commercialization of the technology or change in ownership. The firm primarily funds companies located in the United States but will consider opportunities located globally as well. The firm provides equity capital and does look for a return though percentages taken are generally less than more financially motivated investors and all profits are reinvested back into the fund. Ideally the firm would like to allocate to 3-4 companies over the next 6-9 months.
Website:
www.fightblindness.org
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Tom Capetan
Business Development 

Genrich

Genrich is a Multi-Family office founded and based in Long Beach California with additional offices in New York Toronto and London. The firm is looking to make equity and venture debt investments into companies in the life science space ranging from $2-$2 million over the lifetime of the investment often set up in tranches. Ideal candidates will be located 2 hours driving distance from one of the firm?s offices Boston and Chicago will also be considered. The firm is actively seeking new investment opportunities.
Website:
www.genrichinc.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
John Nelson
Managing Director 

Global Connectworks Ltd. Canada

STRATEGIC CONNECTIONS. CREATIVE SOLUTIONS. Manage your company outreach to investors and partners.

Connecting companies with the right people to build strategic alliances with global partners and investors. Supporting international life science companies in cross border corporate development, financing, investor relations and conference participation. A proven track record leveraging an extensive global network of CEOs, investors and partners into strategic alliances that support business imperatives. CORPORATE DEVELOPMENT - Connecting companies with potential investors and business development opportunities. CONFERENCE ADVISOR Program - A customized program to optimize company participation at key events and conferences to, maximize value and achieve tangible results including online partnering management and management of all conference outreach. 

Website:
www.globalconnectworks.com
Service Provider Type
Sector Interest
Unique Capabilities

Leverage an extensive network for my clients.

Betsy Bascom
President & CEO 

Golden Seeds

Golden Seeds is an investment group that was founded in 25 and is headquartered in New York with other offices in Boston Silicon Valley and Texas. The group currently invests out of the Golden Seeds angel network and the Golden Seeds venture funds. The group has managed 3 venture funds that are Golden Seeds Fund LP Golden Seeds Fund 2 LP and Innovate New York LP Fund. The Golden Seeds angel network has 32 members of which 1 are life science investors. Golden Seeds invests in companies with a female founder or CEO or with women in other C-level positions or with at least 1% of equity owned by women. Golden Seeds prefers to invest in companies with a valuation under $5 million, the group?s first-round equity investments generally range from $ .25 million to $2 million. The group invests in companies based across the US and Canada.
Website:
www.gmail.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Bill Whitaker
Managing Director Co-Chair Life Science Section 

Green Park & Golf Ventures

Green Park & Golf Ventures (GPG) is a family office based in Dallas Texas. The firm was founded in 211 and is focused on healthcare companies. The firm makes seed venture and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $1K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.
Website:
www.gpgventures.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Clay Heighten
Founding Partner 
JR Garcia
Principal 
Carl Soderstrom
Founding Partner 

Greenhouse Capital Partners United States

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.

Website:
http://greenhousecapital.net/
Year Founded
2006
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Eric Desai
Principal 

H.I.G. BioVentures

H.I.G. BioVentures is the life science investment affiliate of H.I.G. Capital and has offices across the USA. H.I.G. BioVentures has assets under management of $4m and is investing from its second fund which closed at $268m in 212. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $2m over the life of an investment. While most of H.I.G. BioVentures? portfolio companies are US-based the firm will consider opportunities worldwide.
Website:
www.higbio.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Enoch Kariuki
Vice President